Guggenheim Boosts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $122.00

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) had its price objective upped by Guggenheim from $100.00 to $122.00 in a research report released on Wednesday morning, The Fly reports.

A number of other analysts have also recently weighed in on SRPT. The Goldman Sachs Group cut their price objective on shares of Sarepta Therapeutics from $181.00 to $155.00 and set a buy rating on the stock in a report on Tuesday, May 24th. StockNews.com lowered shares of Sarepta Therapeutics from a buy rating to a hold rating in a research report on Saturday, May 21st. Needham & Company LLC raised their target price on shares of Sarepta Therapeutics from $150.00 to $162.00 and gave the stock a buy rating in a research report on Friday, July 29th. Cantor Fitzgerald lowered their price objective on shares of Sarepta Therapeutics from $140.00 to $128.00 and set an overweight rating on the stock in a research report on Friday, June 24th. Finally, Credit Suisse Group lifted their price objective on shares of Sarepta Therapeutics from $90.00 to $93.00 and gave the company a neutral rating in a research report on Wednesday. Four equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of Moderate Buy and an average price target of $126.92.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT opened at $106.02 on Wednesday. The firm’s 50 day moving average price is $78.23 and its 200 day moving average price is $76.58. Sarepta Therapeutics has a fifty-two week low of $61.28 and a fifty-two week high of $107.03. The company has a quick ratio of 5.13, a current ratio of 4.53 and a debt-to-equity ratio of 1.52.

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last released its quarterly earnings data on Wednesday, May 4th. The biotechnology company reported ($1.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.35) by $0.15. Sarepta Therapeutics had a negative net margin of 60.66% and a negative return on equity of 67.98%. The company had revenue of $210.83 million for the quarter, compared to analysts’ expectations of $208.25 million. During the same quarter last year, the company earned ($2.10) earnings per share. The firm’s revenue for the quarter was up 43.5% on a year-over-year basis. Equities research analysts predict that Sarepta Therapeutics will post -4.77 EPS for the current fiscal year.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors have recently made changes to their positions in the stock. Exchange Traded Concepts LLC boosted its position in shares of Sarepta Therapeutics by 191.7% during the 2nd quarter. Exchange Traded Concepts LLC now owns 633 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 416 shares in the last quarter. UMB Bank N A MO acquired a new position in shares of Sarepta Therapeutics during the 4th quarter worth $69,000. IndexIQ Advisors LLC acquired a new position in shares of Sarepta Therapeutics during the 1st quarter worth $61,000. KRS Capital Management LLC acquired a new position in shares of Sarepta Therapeutics during the 4th quarter worth $96,000. Finally, Laurel Wealth Planning LLC acquired a new position in shares of Sarepta Therapeutics during the 1st quarter worth $117,000. 81.43% of the stock is currently owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

(Get Rating)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.